No Data
No Data
No Data
No Data
No Data
Quest Diagnostics, LabCorp Climb Following FDA Testing Oversight Rule
Seeking AlphaApr 29 23:45
Laboratory Corporation of America on Pace for Largest Percent Increase Since November 2022 -- Data Talk
Laboratory Corporation of America Holdings (LH) is currently at $206.91, up $8.51 or 4.29% --On pace for largest percent increase since Nov. 10, 2022, when it rose 5.44% --Currently up two consecuti
Dow JonesApr 29 22:28
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With
BenzingaApr 29 22:25
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved He
BenzingaApr 29 19:04
Labcorp Receives FDA Approval for First Companion Diagnostic for Use With Pfizer's Newly Approved Gene Therapy to Treat Patients With Hemophilia B
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA)...
PR NewswireApr 29 19:00
Analyst Ratings For Laboratory Corp
In the latest quarter, 5 analysts provided ratings for Laboratory Corp (NYSE:LH), showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent ratings,
BenzingaApr 27 03:00
No Data
No Data